https://www.selleckchem.com/pr....oducts/r-gne-140.htm
To prevent infusion-related reactions (IRRs), H1-antihistamines (H AT) are recommended as a premedication for monoclonal antibodies, such as Ramucirumab (RAM), even though there are H AT-related side effects, such as drowsiness and dizziness. Here, we investigated the safety of H AT-free RAM regimens in patients with solid cancer. We retrospectively reviewed the patients with solid cancer receiving RAM without H AT at Osaka Medical College Hospital between 2015 and 2019. Among the 123 registered patients, 58 were identified as eligibl
Like
Comment
Share
